Clinical Trials Currently Open

Clinical Research Trials

Research Studies for Dermatologic Conditions

Advanced Dermatology and Cosmetic Surgery is a multi-state dermatology practice with more than 155 locations nationwide. The Clinical Research Division was founded to find new and better ways to treat patients with dermatologic conditions through FDA-supervised clinical trials of leading-edge drugs, devices and other treatments.

Melanoma Chart Review Study

Males and Females, Ages 18 - 90. Qualifying patients have or have had melanoma skin cancer.

Melanoma skin cancer is a type of skin cancer originating from melanocytes, the cells that produce pigment. The Decision DX Melanoma diagnostic test is used to assess the risk of metastasis and recurrence in patients with melanoma by analyzing the tumor's genetic profile.

Submit Your Interest

Study Details

Participating patients must be diagnosed with Melanoma skin cancer with a Decision DX melanoma diagnostic test. This is a Melanoma chart review study, a research method involving the analysis of medical records (charts) of patients diagnosed with melanoma. The goal is to gather and evaluate data on patient demographics, treatment outcomes, disease progression, and other relevant clinical information to draw conclusions about the effectiveness of treatments, patient prognoses, or trends in melanoma care.

Compensation: TBD
Duration: 10 year study, chart review every 6 months
Visits: none

Research Studies at Warren, Michigan

Grekin Skin Institute-Warren
13450 E. 12 Mile Road
Warren, MI 48088

The following clinical trials, under the direction of Dr. Steven Grekin, are open and requesting participants who live in or near Warren or can travel here. Dr. Grekin, founder of The Grekin Skin Institute, has been involved in Clinical Research for drug and device development since 2002. He continues a family legacy of providing extraordinary dermatologic care and treatment which dates back through more than 100 years of physicians, including seven dermatologists.

Submit Your Interest

Alopecia Areata (Hair Loss)

Males and Females, Ages 12+ years old. Qualifying patients will have been diagnosed with Alopecia Areata (AA).

Alopecia areata (AA) is an autoimmune, inflammatory disorder which causes transient, non-scarring hair loss and preservation of the hair follicle.

Study Details

Alopecia Areata Extend Study: This is a non-interventional multicenter, prospective patient outcomes study combined with a retrospective medical chart review of patients initiating treatment with ritlecitinib, baricitinib or traditional therapies. Data collection will take place over the 12 months following a patient’s initiation of treatment.

Compensation: up to $250
Duration: 12 monts

Nasolabial Fold Dermal Filler Study

Males and Females, Ages 22+. Qualifying patients will have moderate to severe nasolabial folds (crease from the bottom of the nostril area to the corner of the mouth).

Study Details

A prospective, multi-center, randomized, controlled, double-blind, split-face study of the safety and effectiveness of a new dermal filler in the treatment of nasolabial folds.

Compensation: up to $850
Duration: 100 weeks
Visits: 16

Atopic Dermatitis (Eczema)

Males and Females, Ages 18 and up. Qualifying patients will have moderate to severe atopic dermatitis (eczema).

Atopic dermatitis, also known as eczema, is a chronic, inflammatory skin condition that's common in young children, but can occur at any age. It may cause itchiness, dry skin, rashes, scaly patches, thickening of the skin, blisters, and skin infections. This condition can weaken your skin’s barrier function, which helps your skin retain moisture and protects your body from outside elements. While there is no cure for eczema, dermatologists specialize in managing its symptoms through various treatments.

Study Details

Grekin Skin Institute is enrolling adults for a double-blind, randomized, placebo treatment controlled study. The study will last 16 weeks with an 8-week follow up. There is no cost to participate, and insurance is not required. Qualified participants will be under the supervision of a board-certified dermatologist and receive up to $1,300 compensation for time and travel.

Compensation: $1,300
Duration: 24 Weeks
Visits: 10

Research Studies at Spartanburg, South Carolina

Advanced Dermatology and Cosmetic Surgery
1650 Skylyn Dr, Ste 402
Spartanburg, SC 29307

Submit Your Interest

Generalized Pustular Psoriasis (GPP)

Males and Females, Ages 18+ years old. Qualifying patients will have been diagnosed with Generalized Pustular Psoriasis (GPP).

GPP is a rare, severe form of pustular psoriasis. It is characterized by sudden widespread eruption of rash and sterile pustules with or without systemic inflammation and erythematous, painful skin. GPP can be associated with systemic inflammation including fevers and/or hepatic, gastrointestinal, musculoskeletal, renal, or pulmonary involvement.

Study Details

This is a prospective, observational registry that seeks to obtain information on the treatment patterns, and adverse events in a cohort of GPP patients. Data collected will be used to better characterize the natural history and longitudinal trajectory of the disease. This will be done through the standardized collection of validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns.

Compensation: $25 per completed visit
Duration: Every 6 monts
Visits: 12

Alopecia Areata (Hair Loss)

Males and Females, Ages 12-18 years old. Qualifying patients will have a diagnosis of primarily diffuse type Alopecia Areata (AA).

AA is an autoimmune disease that causes hair loss due to the immune system attacking hair follicles. It typically presents with discrete bald patches on the scalp but can affect all hair-bearing areas on the body. The exact cause is unclear, but it involves a loss of immune privilege in hair follicles, allowing autoantigens to be presented to autoreactive CD8+ T cells. Risk factors include certain susceptibility genes, family history of autoimmune disorders, and genetic makeup.

Study Details

This AA study is a 1-year long clinical trial that aims to evaluate the efficacy, safety, and tolerability of upadacitinib in extended treatment in adolescent subjects with severe AA. Eligible participants will randomly receive either the investigational drug under study or placebo. The study involves around 32 visits, and those who complete it may have the option to join a long-term extension study to continue receiving the investigational drug under study.

Compensation (participant): $75 per completed visit
Compensation (caregive): $75 per completed visit
Duration: 52 weeks
Visits: 9

Alopecia Areata (Hair Loss)

Males and Females, Ages 18+ years old. Qualifying patients will have Alopecia Areata (AA) diagnosed at least 6 months ago and been prescribed a new medication within the past 12 months.

Alopecia Areata (AA) is an autoimmune disease that causes hair loss due to the immune system attacking hair follicles. It typically presents with discrete bald patches on the scalp but can affect all hair-bearing areas on the body. The exact cause is unclear, but it involves a loss of immune privilege in hair follicles, allowing autoantigens to be presented to autoreactive CD8+ T cells. Risk factors include certain susceptibility genes, family history of autoimmune disorders, and genetic makeup.

Study Details

This is a prospective, observational registry study that seeks to create a cohort of AA patients to study the long-term safety and effectiveness of AA medications. Further, data collected will inform clinical decision making by patients and treating providers. This will be done through the standardized collection of validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns.

Compensation: $25 per completed visit
Duration: Every 6 monts
Visits: 12

Hidradenitis Suppurativa (Acne Inversa)

Males and Females, Ages 16+ years old. Qualifying patients will have moderate to severe Hidradenitis Suppurativa.

Hidradenitis suppurativa is a chronic inflammatory skin condition characterized by painful, swollen lumps that can rupture and cause abscesses, often occurring in areas where skin rubs together, such as the armpits, groin, and under the breasts.

Study Details

The INTREPID HS Study is a year-long clinical trial that aims to evaluate the safety and effectiveness of an investigational drug compared to a placebo in reducing symptoms and improving the quality of life for people with HS. Eligible participants will randomly receive either the investigational drug or a placebo for 16 weeks through weekly subcutaneous injections. After 16 weeks, all participants will receive the investigational drug, either weekly or every other week. The study involves around 18 visits, and those who complete it may have the option to join a long-term extension study to continue receiving the investigational drug. Visit Hidradenitis Suppurativa Clinical Research Study online or contact the study team to learn more.

Compensation: up to $2,400
Duration: 52 weeks
Visits: 32

Atopic Dermatitis (Eczema)

Males and Females, Ages 18 - 64. Qualifying patients will have moderate to severe atopic dermatitis (eczema) diagnosed at least 3 years ago.

AD is a chronic skin condition that can cause dry, itchy patches, discoloration of the skin, and inflammation. The SWITCH-UP Study is evaluating an approved drug for adults whose AD has not improved with previous treatment.

Study Details

The SWITCH-UP Study is evaluating the safety and efficacy of an approved drug compared to another approved drug in participants with atopic dermatitis (AD). The research study will involve 9 study visits and 4 phone calls over the course of up to 9 months. There is no placebo in this research study - participants will always be on an active treatment that will be adjusted or changed depending on their clinical response. Visit The SWITCH-UP Study | Atopic Dermatitis Clinical Research Study online or contact the study team to learn more.

Compensation: $675
Duration: 32 Weeks
Visits: 9

Atopic Dermatitis (Eczema)

Males and Females, Ages 12+. Qualifying patients will have diagnosed Atopic Dermatitis (AD) and prescribed to initiate a new systemic treatment for AD during their office visit at the Advanced Dermatology and Cosmetic Surgery location in Spartanburg.

AD is a chronic, relapsing inflammatory skin disease that significantly burdens the patient’s quality of life. To qualify for this study, patients will be switched or initiated on a new systemic treatment (such as biologics, oral Janus kinase (JAK) inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil) by a qualified healthcare provider.

Study Details

The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions.

Compensation: $72-$80 per completed visit
Duration: Every 3-6 months, 60 months total
Visits: 13

Atopic Dermatitis (Eczema)

Males and Females, Ages 12+. Qualifying patients will have moderate to severe atopic dermatitis (eczema) diagnosed at least 6 months ago.

AD is a chronic, relapsing inflammatory skin disease that significantly burdens the patient’s quality of life. Lebrikizumab is a systemic, novel, subcutaneously injected IgG4 monoclonal antibody selectively targeting Interleukin-13 with high binding affinity and slow off-rate, as demonstrated by efficacy and safety in patients with moderate-to-severe AD in clinical studies.

Study Details

This is an observational study that seeks to understand the effects of lebrikizumab therapy on the treatment of pediatric and adult participants diagnosed with moderate-to-severe Atopic Dermatitis (AD). The research study will involve 8 study visits over the course of 24 months. Since this is an observational study, visits will align with routine care and subjects will only be required to fill out surveys and perform assessments during their visits.

Compensation: $672
Duration: 24 Weeks
Visits: 8

Cold Induced Urticaria and Symptomatic Dermographism

Males and Females, Ages 18+. Qualifying patients will have either Cold Induced Urticaria (ColdU) or Symptomatic Dermographism (SD) diagnosed at least 3 months ago that remains uncontrolled despite a stable dose and regimen of a second-generation non-sedating H1AH medication.

ColdU causes itchy, red, swollen welts after exposure to cold air, water, or objects. SD causes burning or itchy stripe-like hives after rubbing, scratching, or pressure on the skin.

Study Details

The purpose of this study is to evaluate whether an investigational medication called barzolvolimab may help reduce symptoms of ColdU and SD and to learn more about its safety. Participation in this study may last up to 44 weeks and include a screening, as well as multiple treatment and follow-up visits. Some participants may also be invited to take part in a long-term extension study, which would provide additional opportunities to receive the investigational medication and be monitored over a longer period of time.

Compensation: $99-$124 per completed visit
Duration: 44 Weeks
Visits: 12

Research Studies at Denver, Colorado

Cara Mia Dermatology
3540 S Poplar St, Ste 300
Denver, CO 80237

Submit Your Interest

Atopic Dermatitis

Males and Females, Ages 18+ years old. Qualifying patients will have a diagnosis of Atopic Dermatitis by a dermatologist or qualified dermatology provider and has been prescribed an eligible medication.

AD is a chronic skin condition that can cause dry, itchy patches, discoloration of the skin, and inflammation. This trial is evaluating an approved drug for adults whose AD has not improved with previous treatment.

Study Details

The objective of the CorEvitas Atopic Dermatitis (AD) Registry is to create a national cohort of patients with atopic dermatitis. Data collected will be used to extensively evaluate the effectiveness and safety of medications used to treat atopic dermatitis. This will be done through the standardized collection of patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), and the prevalence and incidence of comorbidities and adverse events, medication utilization patterns, and patient productivity measures.

Compensation: $25 per completed visit
Duration: Every 6 months
Visits: 12

Atopic Dermatitis (AD or Eczema)

Males and Females, Ages 18+ years old. Qualifying patients will have a diagnosis of Atopic Dermatitis by a dermatologist or qualified dermatology provider and has been prescribed an eligible medication.

AD is a chronic, relapsing inflammatory skin disease that significantly burdens the patient’s quality of life.

Study Details

This is a study of post approval drug safety and effectiveness with an optional biorepository. There will be no visits required outside of the patient’s standard of care.

Compensation: $25 per routine standard of care visit post enrollment in the study and $100 for the biorepository

Chronic Spontaneous Urticaria (Hives)

Males and Females, Ages 18+ years old. Qualifying patients will present with chronic spontaneous urticaria (hives).

Chronic urticaria is a condition characterized by the presence of hives, or wheals, on the skin that last for more than six weeks, often accompanied by itching and swelling.

Study Details

This is a non-interventional prospective, multi-country, effectiveness and safety study to evaluate the treatment of chronic spontaneous urticaria.

Compensation: Up to $461
Duration: 2 years

Lichen Planopilaris (LPP)

Males and Females, Ages 18+ years old. Qualifying patients will present with a histologically confirmed diagnosis of lichen planopilaris (LPP).

LPP is an autoimmune inflammatory condition that causes scarring and permanent hair loss on the scalp by destroying hair follicles. It leads to symptoms such as redness and scale around hair follicles, itching, burning, tenderness, and bald patches.

Study Details

This is a phase 2/3 randomized, double-blind, placebo-controlled study to investigate the safety and efficacy of oral investigational drug in adults with LPP. Enrolled subjects will participate in a 24-week blinded treatment period and then have the option to continue in an open label extension lasting an additional 24-weeks.

Compensation: Up to $1,125
Duration: Up to 56 weeks
Visits: 13

Coming Soon! Research Studies at Deland, Florida

Advanced Dermatology and Cosmetic Surgery
600 W Plymouth Ave
Deland, FL 32720

Submit Your Interest

Coming Soon! Research Studies at Henderson, Nevada

Advanced Dermatology and Cosmetic Surgery
861 Coronado Center Dr, Ste 100
Henderson, NV 89052

Submit Your Interest

Hidradenitis Suppurativa (Acne Inversa)

Males and Females, Ages 16+ years old. Qualifying patients will have moderate-to-severe Hidradenitis Suppurativa.

Hidradenitis suppurativa is a chronic inflammatory skin condition characterized by painful, swollen lumps that can rupture and cause abscesses, often occurring in areas where skin rubs together, such as the armpits, groin, and under the breasts.

Study Details

This HS Study is a year-long clinical trial that aims to evaluate the safety and effectiveness of an investigational drug compared to a placebo in reducing symptoms and improving the quality of life for people with HS. Eligible participants will randomly receive either the investigational drug or a placebo for 16 weeks through weekly subcutaneous injections. After 16 weeks, all participants will receive the investigational drug, either weekly or every other week. The study involves around 32 visits, and those who complete it may have the option to join a long-term extension study to continue receiving the investigational drug.

Compensation: up to $2,400
Duration: 52 weeks
Visits: 32

Atopic Dermatitis

Males and Females, Ages 18 – 64 years old. Qualifying patients will have moderate-to-severe Atopic Dermatitis (AD) diagnosed at least 3 years ago.

AD is a chronic skin condition that can cause dry, itchy patches, discoloration of the skin, and inflammation. This trial is evaluating an approved drug for adults whose AD has not improved with previous treatment.

Study Details

This research study is evaluating the safety and efficacy of an approved drug compared to another approved drug in participants with atopic dermatitis (AD). The clinical trial will involve 9 study visits and 4 phone calls over the course of up to 9 months. There is no placebo in this research study - participants will always be on active treatment that will be adjusted or changed depending on their clinical response.

Compensation: up to $675
Duration: 32 weeks
Visits: 9

Atopic Dermatitis

Males and Females, Ages 12+ years old. Qualifying patients will have moderate-to-severe Atopic Dermatitis (AD) diagnosed at least 6 months ago.

AD is a chronic, relapsing inflammatory skin disease that significantly burdens the patient’s quality of life. Lebrikizumab is a systemic, novel, subcutaneously injected IgG4 monoclonal antibody selectively targeting Interleukin-13 with high binding affinity and slow off-rate, as demonstrated by efficacy and safety in patients with moderate-to-severe AD in clinical studies.

Study Details

This is an observational study that seeks to understand the effects of lebrikizumab therapy on the treatment of pediatric and adult participants diagnosed with moderate-to-severe Atopic Dermatitis (AD). The research study will involve 8 study visits over the course of 24 months. Since this is an observational study, visits will align with routine care and subjects will only be required to fill out surveys and perform assessments during their visits.

Compensation: up to $672
Duration: 24 months
Visits: 8

Alopecia Areata

Males and Females, Ages 18+ years old. Qualifying patients will have Alopecia Areata (AA) diagnosed at least 6 months ago and been prescribed a new medication within the past 12 months.

AA is an autoimmune disease that causes hair loss due to the immune system attacking hair follicles. It typically presents with discrete bald patches on the scalp but can affect all hair-bearing areas on the body. The exact cause is unclear, but it involves a loss of immune privilege in hair follicles, allowing autoantigens to be presented to autoreactive CD8+ T cells. Risk factors include certain susceptibility genes, family history of autoimmune disorders, and genetic makeup.

Study Details

This is a prospective, observational registry study that seeks to create a cohort of AA patients to study the long-term safety and effectiveness of AA medications. Further, data collected will inform clinical decision making by patients and treating providers. This will be done through the standardized collection of validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns.

Compensation: $25 per completed visit
Duration: Every 6 months
Visits: 12

Generalized Pustular Psoriasis

Males and Females, Ages 18+ years old. Qualifying patients will have Alopecia Areata (AA) diagnosed at least 6 months ago and been prescribed a new medication within the past 12 months.

GPP is a rare, severe form of pustular psoriasis. It is characterized by sudden widespread eruption of rash and sterile pustules with or without systemic inflammation and erythematous, painful skin. GPP can be associated with systemic inflammation including fevers and/or hepatic, gastrointestinal, musculoskeletal, renal, or pulmonary involvement.

Study Details

This is a prospective, observational registry that seeks to obtain information on the treatment patterns, and adverse events in a cohort of GPP patients. Data collected will be used to better characterize the natural history and longitudinal trajectory of the disease. This will be done through the standardized collection of validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns.

Compensation: $25 per completed visit
Duration: Every 6 months
Visits: 12

In the News

In the past, our clinical study results indicated that more than one million skin cancers went undiagnosed in 2020 as a result of COVID-19 concerns, and that total-body skin cancer exams are the most effective way to find skin cancers were published nationally in the January 19, 2021 edition of the Journal of the American Academy of Dermatology (JAAD) and Journal of Clinical Oncology^®, an American Society of Clinical Oncology (ASCO) Journal.